Cytomx Therapeutics, Inc.

Zymogenetics, Inc.

University of California

Bristol-myers Squibb Compnay

Bend Research, Inc.

Cell Therapeutics, Inc.

Pfizer Corporation

Other

Bend Reseach, Inc.

James William West

Jason Gary Sagert

Nancy E Stagliano

Olga Vasiljeva

Kathryn Kamath

Stephen James Moore

Patrick Sean Daugherty

Paul Henry Bessette

Daniel Robert Hostetter

Jonathan Alexander Terrett

Henry Bernard Lowman

Scott R Presnell

Dwayne Thomas Friesen

Elizabeth-Edna Mary Menendez

Luc Roland Desnoyers

Julia E Novak

Zeren Gao

Christopher S Piddington

Margaret Thy Luu Nguyen

Jerry Thomas

Richard D Holly

Sanjay Khare

Paul O Sheppard

Charles E Hart

Debra G Gilbertson

Shouchun Liu

Sherry Lynn La Porte

Fred Gluck

Cindy A Sprecher

Ravi Mysore Shanker

Roderick Jack Ray

Steven D Levin

Andrew J Nelson

Scott B McCray

Marshall David Crew

Rodney James Ketner

Kimberly E Shoemaker

David W Leung

Julian B Lo

Kimberly Ann Tipton

Li Mei

Margaret T L Nguyen

Janine M Bilsborough

Walter Christian Babcock

William John Curatolo

Aaron Paul Yamniuk

Brigitte Devaux

James A S Nightingale

David Keith Lyon

Katherine E Lewis

Brenda L Stevens

Leah Elizabeth Appel

Shrikant Deshpande

Bryan C Barnhart

Cameron Brandt

Steven K Burkhead

Shweta Singh

Robert Mabry

Eric Chadwick

Annie Yang Weaver

Jeanne Grace Flandez

Shannon Lee Okada

Christopher K Tompkins

Robert P Barss

Kendall R Pearson

Delores R Sidwell

John J Englehardt

Stacey Tannheimer

J Peter Klein

Anil M Kumar

Gail E Underiner

David D Newbold

Scott Max Herbig

Joshua R Shockey

Bryan Allen Irving

Frederick J Ramsdell

Chanty Mariategue Chan

Chihunt Wong

Frederick W Gluck

Brent Meengs

Kimberty E Shoemaker

Eric M Chadwick

Edward D Howard

Chihong Wong

The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.

Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4 antibodies have CTLA-4 binding activity in the tumor microenvironment, where the masking moiety is removed by proteolytic cleavage of the cleavable moiety by tumor-specific proteases, but exhibit greatly reduced binding to CTLA-4 outside the tumor. In this way, the activatable anti-human CTLA-4 antibodies of the present invention retain anti-tumor activity while reducing the side effects associated with anti-CTLA-4 activity outside the tumor.

Activatable anti-CTLA-4 antibodies and uses thereof

The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure also provides ABPs which contain a first TBM, a second TBM and a CM. The ABPs exhibit an 'activatable' conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. The disclosure further provides libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. The disclosure further provides ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.

Activatable anti-VEGF scFv

The present invention generally relates to bacterial polypeptide display systems, libraries using these bacterial display systems, and methods of making and using these systems, including methods for improved display of polypeptides on the extracellular surface of bacteria using circularly permuted transmembrane bacterial polypeptides that have been modified to increase resistance to protease degradation and to enhance polypeptide display characteristics.

Protease-resistant systems for polypeptide display and methods of making and using thereof

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Anti-CD40 antibodies and uses thereof

The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Activatable antibodies that bind epidermal growth factor receptor and methods thereof

The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof

The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof

The invention relates generally to multispecific antibodies and to multispecific activatable antibodies that specifically bind to two or more different antigens or epitopes, as well as to methods of making and using these multispecific antibodies and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Multispecific antibodies, multispecific activatable antibodies and methods of using the same

Growing community of inventors

Bend, OR, United States of America

James William West